News
CPRX
7.06
+0.71%
0.05
Insider Sell: Catalyst Pharmaceuticals
MT Newswires · 06/23 17:10
Catalyst (CPRX) Up 6.9% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 06/09 15:30
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
CORAL GABLES, Fla., May 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with ...
GlobeNewswire · 05/17 12:03
Most likely large-cap and small-cap merger candidates -BofA
BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based
Seekingalpha · 05/15 15:42
Catalyst Pharmaceuticals Q1 earnings rise Y/Y; reaffirms FY22 revenue outlook
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q1 non-GAAP EPS grew +63.64% Y/Y to $0.18 and the company reaffirmed its FY22 revenue outlook. Total revenues rose +42.66% to $43.03M Y/Y. The company said the increase
Seekingalpha · 05/11 16:49
Catalyst Pharmaceuticals (NASDAQ:CPRX) pulls back 10% this week, but still delivers shareholders solid 27% CAGR over 5 years
Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX ) shareholders might be concerned after seeing the share price drop 14% in...
Simply Wall St. · 05/11 10:05
Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings and Revenue Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of -14.29% and 0.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 21:25
Catalyst Pharmaceuticals Q1 EPS $0.18 Beats $0.14 Estimate, Sales $43.10M Beat $42.75M Estimate
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.14 by 28.57 percent. This is a 157.14 percent increase over earnings of $0.07 per
Benzinga · 05/10 20:55
Catalyst Pharmaceuticals Non-GAAP EPS of $0.18, revenue of $43.09M
Catalyst Pharmaceuticals press release (NASDAQ:CPRX): Q1 Non-GAAP EPS of $0.18. Revenue of $43.09M (+42.6% Y/Y). Shares +1.6%. Guidance: The Company continues to forecast full year 2022 total revenues to be
Seekingalpha · 05/10 20:15
BRIEF-Catalyst Pharmaceuticals Reports First Quarter 2022 Results
reuters.com · 05/10 20:15
-- Earnings Flash (CPRX) CATALYST PHARMACEUTICALS Reports Q1 EPS $0.18, vs. Street Est of $0.14
MT Newswires · 05/10 16:23
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/10 13:23
Earnings Scheduled For May 10, 2022
  Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Benzinga · 05/10 09:18
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -13.99% and 8.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 21:45
Catalyst Pharmaceuticals Q1 2022 Earnings Preview
Catalyst Pharmaceuticals (NASDAQ:CPRX) is scheduled to announce Q1 earnings results on Tuesday, May 10th, after market close. The consensus EPS Estimate is $0.14 (+27.3% Y/Y) and the consensus Revenue Estimate
Seekingalpha · 05/09 21:35
Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022
The Company to Host a Conference Call and Webcast on May 11, 2022, at 8:30 AM ETCORAL GABLES, Fla., April 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-li...
GlobeNewswire · 04/25 12:03
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Catalyst Pharmaceuticals (NASDAQ:CPRX) has had a great run on the share market with its stock up by a significant 13...
Simply Wall St. · 03/29 21:15
This Coal Company's 1-Year Return Handily Beats Moderna, Catalyst Pharmaceuticals, Globalstar And Dogecoin
Alpha Metallurgical Resources Inc (NYSE: AMR) is known as a leading American coal supplier, and over the past year, delivered shocking returns for bullish traders and investors.
Benzinga · 03/26 21:05
Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings
Benzinga · 03/17 18:17
Sector Update: Health Care Stocks Easing as Other Sectors Gain
MT Newswires · 03/17 16:11
More
Webull provides a variety of real-time CPRX stock news. You can receive the latest news about Catalyst Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With the patient focus, the Company is engaged in developing a robust pipeline of cutting-edge, medicines for rare diseases. The Company's New Drug Application for FIRDAPSE (amifampridine) tablets 10 milligrams (mg) for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS). The Company's FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. The FIRDAPSE is also used for the treatment of adult patients in Canada with LEMS. The Company is also focused on initiating clinical trials of amifampridine in other ultra-rare neuromuscular conditions.